Michael H Carrel Atri Cure, Inc. (ATRC) insider trading activity

Michael H Carrel is President, CEO, & Director of AtriCure, Inc.. Currently has a direct ownership of 707,377 shares of ATRC, which is worth approximately $25.5 Million. The most recent transaction as insider was on Jun 30, 2025, when has been sold 822 shares (Common Stock) at a price of $25.84 per share, resulting in proceeds of $21,240. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 707K

0.12% 3M change

8.29% 12M change

Total Value Held $25.5 Million

MICHAEL H CARREL Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 30 2025	BUY Grant, award, or other acquisition	$21,240 $25.84 p/Share	822 Added 0.12%	707,377 Common Stock
Mar 10 2025	SELL Bona fide gift	-	4,000 Reduced 0.56%	706,555 Common Stock
Mar 01 2025	SELL Payment of exercise price or tax liability	$1,701,693 $38.74 p/Share	43,926 Reduced 5.82%	710,555 Common Stock
Mar 01 2025	BUY Grant, award, or other acquisition	-	101,242 Added 11.83%	754,481 Common Stock
Aug 14 2024	SELL Bona fide gift	-	3,000 Reduced 0.46%	653,239 Common Stock
Jun 28 2024	BUY Grant, award, or other acquisition	$13,680 $19.35 p/Share	707 Added 0.11%	656,239 Common Stock
Mar 14 2024	SELL Bona fide gift	-	2,000 Reduced 0.3%	655,532 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$1,735,054 $36.28 p/Share	47,824 Reduced 6.78%	657,532 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	119,996 Added 14.54%	705,356 Common Stock
Nov 27 2023	SELL Bona fide gift	-	10,000 Reduced 1.68%	585,360 Common Stock
Aug 04 2023	SELL Bona fide gift	-	1,250 Reduced 0.21%	595,360 Common Stock
Jun 30 2023	BUY Grant, award, or other acquisition	$21,227 $38.11 p/Share	557 Added 0.09%	596,610 Common Stock
May 31 2023	SELL Bona fide gift	-	1,000 Reduced 0.17%	596,053 Common Stock
Mar 01 2023	SELL Bona fide gift	-	1,600 Reduced 0.27%	597,053 Common Stock
Mar 01 2023	SELL Payment of exercise price or tax liability	$1,764,690 $38.81 p/Share	45,470 Reduced 7.06%	598,653 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	115,227 Added 15.17%	644,123 Common Stock
Nov 17 2022	SELL Bona fide gift	-	6,000 Reduced 1.12%	528,896 Common Stock
Jun 30 2022	BUY Grant, award, or other acquisition	$12,155 $34.73 p/Share	350 Added 0.07%	534,896 Common Stock
Mar 01 2022	SELL Payment of exercise price or tax liability	$3,003,991 $69.59 p/Share	43,167 Reduced 7.47%	534,546 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	89,741 Added 13.45%	577,713 Common Stock
Feb 24 2022	SELL Bona fide gift	-	1,020 Reduced 0.21%	487,972 Common Stock
Dec 31 2021	BUY Grant, award, or other acquisition	$8,333 $59.1 p/Share	141 Added 0.03%	488,992 Common Stock
Dec 07 2021	SELL Bona fide gift	-	10,000 Reduced 2.0%	488,851 Common Stock
Nov 12 2021	SELL Bona fide gift	-	345 Reduced 0.07%	498,851 Common Stock
Nov 10 2021	SELL Bona fide gift	-	345 Reduced 0.07%	499,196 Common Stock

Also insider at

AXNX

Axonics, Inc. Healthcare

MHC

Michael H Carrel

President, CEO, & Director

Mason, OH

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ATRC shares.

Notify only if

Value

Insider Trading

Get notified when an Atri Cure, Inc. insider buys or sells ATRC shares.

Notify only if

Operation

Value

Type

News

Receive news related to AtriCure, Inc.

Track Activities on ATRC

Account